Turning rare diseases into efficient targets with AIBy Dr Patrick Keohane (Chief Medical Officer: BenevolentBio)
Issue #1 2017 Targeting GAS6 in cancer, fibrosis and viral infectionBy Rebecca Miao/ Amato J Giaccia (Stanford University) and Raymond Tabibiazar (Aravive Biologics Inc)
Issue #1 2017 Nanoparticle-mediated enzyme delivery for application in cancer therapyBy Mukanth Vaidyanathan (University of California), Negin Mokhtari (University of California), Sadik Esener (University of California), Ya-San Yeh (University of California)
Democratising clinical genomics while protecting data privacy By Jurgi Camblong (CEO: Sophia Genetics)
Issue #4 2016 Clinical optimism for antagonists targeting certain ion channelsBy Anindya Bhattacharya (Janssen Research & Development: LLC)
Issue #4 2016 Translational proteomics: from the bench to the bedsideBy Manuel Fuentes (Cancer Research Centre), Paula Díez (Cancer Research Centre)
Issue #4 2016 Exploring the need for mutation-specific treatments in cystic fibrosisBy Caroline Richards (Drug Target Review)
Follow: